Insurer Accuses Jazz Pharma Of 'Grotesque' Antitrust Scheme
A California health care provider accused Jazz Pharmaceuticals of conspiring with competitors to delay generic versions of its Xyrem narcolepsy drug and of instituting "grotesque" price hikes....To view the full article, register now.
Already a subscriber? Click here to view full article